Health Care · Surgical & Medical Instruments & Apparatus · NYSE · CIK 784199 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $27.67Day +0.44%Mkt cap $1.3BP/E (FY) 131.2×1Y −12.4%Off 52W high −42.7%Vol (1Y) 54.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,128 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesNEVER-OBSERVED · 48.3% growth |
| Short interest5.1% of sh out |
| Days to cover4.5d |
| 13F net flow (QoQ)−2.09% |
| Top-10 13F concentration51.0% |
| Next report (est.)2026-08-06 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)131.2× |
| Sales (TTM)$458.7M |
| Earnings (TTM)$11.7M |
| ROE2.7% |
| Net margin2.2% |
| ROIC3.9% |
| YTD−39.3% |
| 1Y−12.4% |
| 3Y+58.8% |
| Since incept. (ann.)+9.8% |
Total return through 2026-07-30 · series begins 2022-01-25. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)54.0% |
| Ann. volatility (3Y)43.7% |
| Sharpe (1Y)0.04 |
| Sharpe (3Y)0.58 |
| Max drawdown (1Y)−57.8% |
| Max drawdown (3Y)−57.8% |
| Beta (3Y vs SPY)1.56 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 6.5M | $237M | 13.52% | +1.7% |
| FMR LLC | 2.6M | $95M | 5.40% | +1.6% |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.5M | $90M | 5.13% | −6.0% |
| MORGAN STANLEY | 2.3M | $83M | 4.74% | +0.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $71M | 4.08% | new |
| STATE STREET CORP | 1.7M | $62M | 3.51% | +6.1% |
| PERCEPTIVE ADVISORS LLC | 1.6M | $60M | 3.42% | −4.9% |
| FRED ALGER MANAGEMENT, LLC | 1.2M | $44M | 2.52% | −12.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | $0.03 | — | $116.3M | +17.5% |
| 2025-12-31 | 2026-02-12 | — | — | $116.0M | +19.2% |
| 2025-09-30 | 2025-11-06 | $0.13 | — | $113.4M | +18.4% |
| 2025-06-30 | 2025-08-07 | $0.03 | — | $113.0M | +15.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
North America 50% · Europe The Middle East And Africa Segments 34% · Asia Pacific 10% · Latin America 5%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Total debt / EBITDA3.83× |
| Sales growth 3Y12.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
